10-Q: Agentix Corp. Faces Going Concern Doubt Amid Rising Losses

Agentix Corp. reported increased net losses and critically low cash for Q1 2026, raising substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $185,824 for the three months ended June 30, 2025, an increase from $150,717 in the prior year period.
• Cash on hand was critically low at $4,412 as of June 30, 2025, down from $4,477 on March 31, 2025.
• Total current liabilities increased to $3,276,178 as of June 30, 2025, up from $3,204,523 as of March 31, 2025.
• Accumulated deficit grew to $6,707,352 as of June 30, 2025, deepening the total stockholders' deficit to $3,271,766.
• Operating expenses rose to $200,342, primarily due to increased research and development costs ($100,000 vs. $55,501) and professional fees ($82,625 vs. $77,000).
• The company has substantial related-party debt, including $1,261,594 owed to SBS Management LLC and $516,262 to Grays Peak Capital, plus a secured note payable of $343,000 to Grays Peak Private Credit LLC.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025.

Sentiment

Score: 1

Explanation: The company faces severe liquidity issues, has a substantial accumulated deficit, is operating at a loss with no revenue, and has expressed substantial doubt about its ability to continue as a going concern. The ineffective disclosure controls further compound the negative outlook.

Positives

• Recognized other income of $20,604, primarily from a gain on the settlement of accounts payable.
• Experienced a foreign exchange gain of $15,140 for the three months ended June 30, 2025.

Negatives

• Reported a net loss of $185,824 for the three months ended June 30, 2025, an increase from $150,717 in the prior year.
• Cash on hand is critically low at $4,412, insufficient to support daily operations.
• Accumulated deficit increased to $6,707,352, and total stockholders' deficit deepened to $3,271,766.
• Negative cash flows from operating activities significantly worsened to $(118,371) from $(2,400) in the prior year period.
• Disclosure controls and procedures were deemed ineffective as of June 30, 2025.
• The company has not generated any revenue for the periods presented.

Risks

• Substantial doubt exists about the ability to continue as a going concern due to accumulated deficit, net loss, negative operating cash flows, and negative working capital.
• Inability to obtain additional financing is a critical risk, as funds are necessary to complete the business plan and cover ongoing operational expenses.
• Potential for significant dilution for existing shareholders if equity financing is pursued to raise capital.
• Risk of unfavorable terms if debt financing is obtained, which could further burden the company's financial position.
• Dependence on related parties for advances and financing, with some advances being unsecured, non-interest bearing, and lacking formal repayment terms.
• General industry and market conditions, product demand, market and customer acceptance, competition, pricing, and development difficulties could materially affect actual results.
• Ineffective disclosure controls and procedures pose a risk to the reliability of financial reporting and regulatory compliance.

Future Outlook

The company needs to raise additional funds to complete its plan of operation and fund ongoing operational expenses for the next 12 months. This funding will likely come from equity or debt financing, with potential for dilution for existing shareholders or unfavorable debt terms. There is no assurance that sufficient funding will be secured, and without it, the business will likely fail.

Management Comments

• "Our management has included projections and estimates in this Form 10-Q, which are based primarily on managements experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the SEC or otherwise publicly available."
• "We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events."
• "Our cash position is not sufficient to support our daily operations, and it will need further funding."
• "The ability of the Company to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds."
• "We cannot provide investors with any assurance that we will be able to raise sufficient funding from the sale of our common stock or obtaining debt to fund our development activities and ongoing operational expenses. If we are unable to achieve the financing necessary to continue our plan of operations, then we will not be able to continue our development to complete our plan of operation and our business will fail."
• "Our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective as of June 30, 2025."

Industry Context

Agentix Corp. operates in the highly capital-intensive clinical-stage biotechnology sector, specifically targeting metabolic diseases like Type 2 diabetes, obesity, NAFLD, and NASH. This industry typically requires significant, sustained R&D investment over many years before potential commercialization, often relying heavily on external financing. The company's current financial state, characterized by zero revenue, increasing losses, and a critical cash shortage, is not uncommon for early-stage biotech firms but highlights an urgent need for substantial capital infusion to progress its therapeutic agents through clinical development, a stage where many promising candidates fail or require extensive funding.

Comparison to Industry Standards

• The company's lack of revenue and significant accumulated deficit are typical for a clinical-stage biotechnology company, as product development is lengthy and costly. However, its extremely low cash balance of $4,412 and negative working capital of over $3.2 million are far below industry norms for companies actively pursuing R&D, indicating an immediate and severe liquidity crisis.
• Compared to peers like Viking Therapeutics (VKNG) or Madrigal Pharmaceuticals (MDGL), which are also developing treatments for metabolic diseases and NAFLD/NASH, Agentix Corp. appears to be at a much earlier stage of development and significantly undercapitalized. These larger, more established peers typically have substantial cash reserves (hundreds of millions) to fund extensive clinical trials and operations for several years.
• The reliance on related-party financing, particularly unsecured, non-interest-bearing advances with no formal repayment terms, suggests a limited ability to secure traditional institutional financing, which is a red flag compared to industry standards where venture capital or public offerings are common for funding R&D.
• The ineffective disclosure controls and procedures are a significant governance weakness, contrasting sharply with the robust internal controls expected of publicly traded companies, even smaller reporting companies.

Corporate Governance

Related Party Transactions

• SBS Management LLC received $96,103 in management consulting fees for the three months ended June 30, 2025.
• Advances from SBS Management LLC to the company totaled $1,261,594 as of June 30, 2025, which are unsecured, non-interest bearing, and lack formal repayment terms.
• Grays Peak Capital made advances to the company totaling $516,262 as of June 30, 2025, which are unsecured, non-interest bearing, and lack formal repayment terms.
• A Mezzanine Secured Note with Grays Peak Private Credit LLC has a principal balance of $343,000 as of June 30, 2025, bearing interest at 2% per month after 30 days, and is secured by all company assets.
• Accrued interest on the Grays Peak Private Credit LLC note was $83,359 as of June 30, 2025.
• $433,497 was included in accounts payable related parties for management as of June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from potential equity financing, and their investment is at high risk due to the going concern doubt and severe financial distress.
• Creditors (including related parties) hold substantial unsecured and secured debt, with some advances lacking formal repayment terms, indicating high exposure to the company's financial instability.
• Employees and management's employment and compensation are directly impacted by the company's ability to continue operations, with significant amounts owed to management in accounts payable.
• Suppliers and vendors face risk of delayed or non-payment due to the company's critical cash shortage and negative working capital.

Next Steps

• Raise additional funds through equity or debt financing to support operations and business plan.
• Implement its business plan and generate sufficient revenue.
• Address the ineffectiveness of disclosure controls and procedures.

Key Dates

Recommendation

Agentix Corp. is in severe financial distress, explicitly stating 'substantial doubt about its ability to continue as a going concern.' The company has zero revenue, increasing net losses, critically low cash ($4,412), and significant negative working capital. Its disclosure controls are ineffective, and it relies heavily on related-party financing with unfavorable terms. The need for immediate, substantial capital raises, with no assurance of success, coupled with the high risk of dilution or unfavorable debt terms, presents an extremely poor investment outlook. For a seasoned investor, these factors warrant a strong sell recommendation or avoidance.

Keywords

Agentix Corp, biotechnology, metabolic disease, Type 2 diabetes, obesity, NAFLD, NASH, SEC filing, 10-Q, financial results, going concern, net loss, cash flow, related party transactions, clinical stage, equity financing, debt financing